The data from the results of a phase-3 clinical trial noted that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw. A targetted three-drug combination therapy could increase the survival period of patients with advanced bowel cancer for overall nine months as […]